Latest News in the pharma Industry

Policy & Regulation

Merck launches Remicade biosimilar for all eligible indications, in the US

Merck launches Remicade biosimilar for all eligible indications, in the US

24 Jul 2017

The biosimilar's list price will represent a 35% discount to the current list price of Remicade.

Read more 
Novartis receives positive CHMP opinion for Rydapt

Novartis receives positive CHMP opinion for Rydapt

23 Jul 2017

If approved, Rydapt would represent the first targeted treatment for newly diagnosed FLT3-mutated AML in the EU.

Read more 
GSK receives FDA approval for a new self-injectable formulation of Benlysta

GSK receives FDA approval for a new self-injectable formulation of Benlysta

23 Jul 2017

The approval marks the first subcutaneous self-injection treatment option for patients with systemic lupus erythematosus.

Read more 
FDA approves new treatment to reduce the risk of breast cancer returning

FDA approves new treatment to reduce the risk of breast cancer returning

18 Jul 2017

Nerlynx is the first extended adjuvant therapy for patients with HER2-positive breast cancer.

Read more 
FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII

FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII

17 Jul 2017

Company expects to launch by the end of the year.

Read more 
FDA committee recommends approval of Mylan and Biocon's proposed biosimilar trastuzumab

FDA committee recommends approval of Mylan and Biocon's proposed biosimilar trastuzumab

16 Jul 2017

Vote marks first proposed biosimilar trastuzumab to be recommended by the committee.

Read more 
Novartis CAR-T cell therapy CTL019 recommended for FDA approval

Novartis CAR-T cell therapy CTL019 recommended for FDA approval

13 Jul 2017

A BLA for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available.

Read more 
FDA accepts sNDA for Xeljanz for the treatment of adult patients with active ulcerative colitis

FDA accepts sNDA for Xeljanz for the treatment of adult patients with active ulcerative colitis

13 Jul 2017

Anticipated Prescription Drug User Fee Act (PDUFA) action date for the sNDA is March 2018 .

Read more 
Lilly reaches settlement agreement in US Cialis patent litigation

Lilly reaches settlement agreement in US Cialis patent litigation

12 Jul 2017

Cialis exclusivity is now expected to end at the earliest on 27 September 2018.

Read more 
FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

12 Jul 2017

Blincyto is the first and only Bispecific T cell Engager (BiTE) immunotherapy to demonstrate superior overall survival versus standard of care chemotherapy.

Read more 
SMC says ‘yes’ to Opdivo for blood cancer patients

SMC says ‘yes’ to Opdivo for blood cancer patients

12 Jul 2017

Patients in Scotland will now join those in England and Wales and be able to benefit from this potentially life-extending immunotherapy on the NHS.

Read more 
BMS's Orencia receives FDA approval for treatment of active psoriatic arthritis in adults

BMS's Orencia receives FDA approval for treatment of active psoriatic arthritis in adults

10 Jul 2017

Orencia now approved in three autoimmune diseases.

Read more